Business
Claritas Announces Approval from Australian Ethics Committee to Begin Phase 1 Trial of R-107
Claritas Announces Approval from Australian Ethics Committee to Begin Phase 1 Trial of R-107.
About this update from Claritas Pharmaceuticals Inc.
[{"type":"text","content":"\n SAN FRANCISCO, CA and TORONTO, ON, April 05, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: CLAZF) (the \"Company\" or \"Claritas\") today announced that the Australian Human Research Ethics Committee has approved the Company’s submission for the Phase 1 clinical study of R-107 to be conducted at Scientia Clinical Research in Sydney, Australia. Claritas will now immediately begin enrollment in the study. Highlights Claritas has received approval of its Phase 1 clinical study of R-107 from the Australian Human Research Ethics Committee (the “HREC”).HREC approval is the final regulatory step prior to initiation of the clinical study.Enrollment of subjects in the clinical study will begin immediately. R-107 is a liquid, nitric oxide-releasing compound with issued and pending composition of matter and method of use patents in approximately 40 countries, including the U.S., Australia, Brazil, China, Europe, India, Japan, Russia and South Korea. Nitric Oxide Therapy Nitric oxide is a natural molecule produced by nearly every cell type in the body. In 1998, nitric oxide was the subject of the Nobel Prize in medicine, and since that time, more than 130,000 peer reviewed articles have been published on nitric oxide and its many biological functions. Inhaled nitric oxide is approved for treatment of persistent pulmonary hypertension of the newborn (“PPHN”). It has also been proposed as a long-term therapy for pulmonary arterial hypertension (“PAH”) in adult patients. R-107 will Transform the Field of Nitric Oxide TherapyNitric oxide exists as a gas and must be delivered by inhalation therapy requiring use of a CPAP-like device and administration by trained respiratory therapists. For these reasons, use of nitric oxide gas is expensive and cumbersome, and therefore its application has been limited. R-107 is a breakthrough compound designed to overcome the limitations of nitric oxide inhalation therapy. Unlike gaseous nitric oxide, R-107 is a liquid that can be administered by mouth (in a capsule), by nasal spray, by nebulizer, by injection, by suppository (vaginally or rectally) or topically (in an ointment). R-107, holds the key to unlocking the full potential of nitric oxide, and we believe it is the only drug in development capable of do...